Table 1.

Methotrexate myelopathy exhibiting subacute combined degeneration-like image findings

Patient number	Age (years)/Sex	Diagnosis	Total dose of intrathecal methotrexate	Methotrexate therapy before intrathecal administration	Clinical course	Symptoms of transverse myelitis	Signal hyperintensity on T2-weighted magnetic resonance imaging	Serum vitamin B12/folic acid	Clinical improvement after vitamin supplementation	Reference
1	28/F	NHL	12mg ×8	+	Subacute	+	C-S (posterior and lateral funiculi)	Normal/normal	Mild	Lu et al. [8]
2	60/F	NHL	12mg ×9	–	Subacute	–	C-S (posterior funiculus)	Normal/N.D.	No	Lu et al. [8]
3	26/F	ALL	12mg ×3	+	Acute	+	C-T (posterior funiculus)	Normal/N.D.	Mild	Counsel and Khangure [9]
4	45/M	ALL	15mg ×7	+	Subacute	+	T-S (posterior and lateral funiculi)	N.D.	No	Honda and Ujihira [10]
5	42/F	ALL	12mg ×2	–	Subacute	–	C-T (posterior and lateral funiculi)	High/normal	No	Gosavi et al. [11]
6	59/M	NHL	14mg ×5	+	Subacute	+	C-T (posterior and lateral funiculi)	Normal/normal	No	Our study

ALL, acute lymphocytic leukemia; C, cervical spinal cord; F, female; M, male; N.D., not determined; NHL, non-Hodgkin lymphoma; S, sacral spinal cord; T, thoracic spinal cord